Decoy Therapeutics is trading 8.78% up now at $3.84 after warning its shortened cash runway could create a potential Nasdaq delisting risk.
- Reported a $2.37 million second-quarter 2026 net loss; its earnings release listed a $2.4 million loss, or $4.46 per share.
- Generated $227,629 in grant revenue, while research and development spending widened losses; the release reported $228,000 in revenue.